European Archives - Page 967 of 1157 - European Medical Journal

Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study

Groningen, The Netherlands, April 20, 2017 – Polyganics, a privately held medical technology company focused on the commercialization of proprietary…

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

Tel-Aviv, Israel, April 18, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty…

Spring Has Sprung!

Once, twice, a thousand times I’ve said it, and yet as a new month rolls around, you can pretty much predict that I’ll comment on how quickly time has…

Could Diabetic Retinopathy be Prevented by Secretogranin III Inhibitors?

VASCULAR changes in diabetic patients can lead to long-term complications including diabetic retinopathy. Researchers from the Bascom Palmer Eye…

Eosinophils: A Potential New Treatment for Type 2 Diabetes Mellitus

EOSINOPHILS, a specific type of immune cell, may present as a new target for the treatment of Type 2 diabetes mellitus and obesity-related hypertension…

LifeCodexx and Charité to Form Research Alliance Following Successful Clinical Proof-Of Principle for Molecular Genetic-Based Preeclampsia Assay

Konstanz/Berlin, Germany, April 11, 2017 – LifeCodexx AG, a leading European NIPT provider, and the Department of Obstetrics of the Charité have formed a…

The UK Should Look to Digital Platforms to Improve Services for Mental Health Sufferers

An online therapy service in Finland is assisting mental health individuals who feel they cannot go to see a therapist/doctor in confidence. First set up…

Vaccine Reduces Risk of Hospitalisation with Shingles

THE RISK of developing shingles (herpes zoster virus), a skin condition that occurs once the varicella-zoster virus is reactivated in nerve cells, can be…

Melanoma, Mutations, and Mice

MELANOMAS with mutations in ATR, a protein that detects and repairs DNA damage caused by ultraviolet exposure and which contributes to cell reproduction…

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

Lausanne, Switzerland, April 06, 2017 – Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases…